The latest budget proposal to cut anti-obesity medication (AOM) coverage by Medi-Cal will cost the state more in the long run ...

WeightWatchers teams up with UK weight-loss drug provider CheqUp in a major shift from its traditional dieting model, amid ...

Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

After adjusting for the weight loss benefits of surgery, GLP-1 drugs were linked to a 41% lower risk of obesity-related ...

A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but ...

The NHS has been urged to accelerate the rollout of weight loss drugs to “many millions” of people, as experts hailed the start of a “golden age” of anti-obesity treatments. A raft of studies ...

The NHS has been urged to accelerate the rollout of weight loss drugs to “many millions” of people, as experts hailed the start of a “golden age” of anti-obesity treatments. A raft of ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...

There is an “unbelievable number of anti-obesity drugs in development,” including GLP-1 receptor agonists with other incretins and appetite suppressants, Bays, chief science officer and ...

A special point of interest for these researchers were the rates of prescribing of anti-obesity medication (AOM) among physicians treating adults versus children. This study was a secondary ...